These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 38412186)

  • 1. Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
    Zafeiropoulou K; Kalampounias G; Alexis S; Anastasopoulos D; Symeonidis A; Katsoris P
    PLoS One; 2024; 19(2):e0289904. PubMed ID: 38412186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
    Niewerth D; Jansen G; Assaraf YG; Zweegman S; Kaspers GJ; Cloos J
    Drug Resist Updat; 2015 Jan; 18():18-35. PubMed ID: 25670156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance.
    Leonardo-Sousa C; Carvalho AN; Guedes RA; Fernandes PMP; Aniceto N; Salvador JAR; Gama MJ; Guedes RC
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
    Citrin R; Foster JB; Teachey DT
    Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
    Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
    Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
    Schlesser C; Meul T; Stathopoulos G; Meiners S
    Biomolecules; 2022 May; 12(6):. PubMed ID: 35740881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
    Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
    Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.
    Kanbur E; Baykal AT; Yerlikaya A
    Med Oncol; 2021 Aug; 38(9):112. PubMed ID: 34363546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
    Robak P; Robak T
    Drugs R D; 2019 Jun; 19(2):73-92. PubMed ID: 30993606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunoproteasome as a therapeutic target for hematological malignancies.
    Miller Z; Lee W; Kim KB
    Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Progress on Molecular Mechanisms of Resistance to Bortezomib in Multiple Myeloma- Review].
    Shi LL; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1576-1579. PubMed ID: 29070146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.